AACR Annual Meeting | Conferences

Test Shows Significance of Screening for Genomic Variants That Could Impact Treatment

April 19, 2018

To help reduce the chance of drug-induced toxicities and improve patient outcomes, NantOmics has developed a test that utilizes pharmacogenomic screening of patients to identify potential genomic variants that could impact treatment decisions. In results from the NantOmics pharmacogenomics test, more than 7% of patients were determined to have a variant that could potentially alter the course of their treatment.

Co-Clinical Trial of Olaparib and Temozolomide in SCLC PDX Models

April 18, 2018

Benjamin J. Drapkin, MD, PhD, clinical fellow in medicine, Dana-Farber Cancer Institute, resident, Massachusetts General Hospital, discusses the co-clinical trial of olaparib (Lynparza) and temozolomide (temodar) in small cell lung cancer (SCLC) patient-derived xenografts (PDX) models during the 2018 AACR Annual Meeting.

Updated Findings Confirm Nivolumab OS Benefit in SCCHN

April 18, 2018

Patients with metastatic or recurrent squamous cell carcinoma of the head and neck experienced a 32% reduction in the risk of death compared with investigator's choice of therapy, according to updated findings with a minimum of 2 years of follow-up from the phase III CheckMate-141 study.

Mutation Burden Predictive of First-Line Immunotherapy Response in NSCLC

April 18, 2018

In an updated analysis of CheckMate-586, investigators found that tumor mutational burden identified patients with non–small cell lung cancer who were more likely to respond to first-line combination immunotherapy with nivolumab and ipilimumab.

Findings With the Antibody Drug Conjugate D3-GPC2-PBD

April 18, 2018

Kristopher Bosse, MD, attending physician, Division of Oncology, The Children's Hospital of Philadelphia, discusses findings with the antibody-drug conjugate (ADC) D3-GPC2-PBD for neuroblastoma presented at the 2018 AACR Annual Meeting.

No Benefit With Addition of Epacadostat in Pancreatic Cancer

April 18, 2018

In findings from the phase I/II ECHO-203 study presented at the 2018 AACR Annual Meeting, there were no clinical responses demonstrated by adding the IDO1 inhibitor epacadostat to the PD-L1 inhibitor durvalumab in patients with pancreatic cancer.

TLR9 Agonist Shows Signs of Reversing Resistance to PD-1 Inhibition in Melanoma

April 17, 2018

According to phase Ib study findings presented at the 2018 AACR Annual Meeting, combining the intratumoral toll-like receptor 9 (TLR9) agonist CMP-001 and pembrolizumab showed clinical activity in reversing PD-1 checkpoint inhibition resistance in patients with metastatic melanoma.

Nivolumab/Ipilimumab Significantly Improves PFS in TMB-High NSCLC

April 17, 2018

The 1-year progression-free survival rate was more than tripled with the combination of nivolumab and ipilimumab versus chemotherapy in treatment-naïve patients with non–small cell lung cancer with high tumor mutation burden, according to initial findings from the phase III CheckMate-227 trial.

Findings With FT819 Demonstrate Promising, Accessible Approach to CAR T-Cell Therapy

April 17, 2018

Findings, presented at the 2018 AACR Annual Meeting, demonstrated that an off-the-shelf, dual-targeted chimeric antigen receptor (CAR) T-cell approach found positive results in preclinical specificity, functionality, and efficacy studies.